Academic & Research Center
Advancing the field of sleep medicine through rigorous clinical trials, physician education, and evidence-based practice.
Clinical research is conducted by DSM Research, LLC, a separate entity from the Dream Sleep Medicine clinical practice. Taking part in a study is always voluntary and separate from your medical care — see what taking part actually means.
Join a Clinical Trial
Get access to tomorrow's sleep treatments today — under the direct care of a board-certified sleep physician, at no cost to you.
Narcolepsy Type 1 (ALKS 2680)
Evaluating the efficacy and safety of the investigational medicine ALKS 2680 (alixorexton) in adults with narcolepsy type 1.
- Duration:
- ~14 weeks plus screening (up to ~22 weeks total, including a paid 2–6 week medication washout)
- Visits:
- Up to 18 visits: 8 clinic visits, 3 overnight sleep-lab stays, 7 phone calls
- Compensation:
- Up to $6,925 – $9,725 if you complete the study (amount depends on washout length), plus $125 for pre-screening. Travel, hotel, and meals reimbursed.
- You may qualify if:
- Adults 18–70 with narcolepsy type 1 (with cataplexy) · more than 4 cataplexy episodes/week · BMI 18–40 · able to pause current narcolepsy medicines (paid washout)
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Narcolepsy Type 2 (ALKS 2680)
Evaluating the efficacy and safety of the investigational medicine ALKS 2680 (alixorexton) in adults with narcolepsy type 2.
- Duration:
- ~20 weeks total, including screening with a paid 2–6 week medication washout and 12 weeks of treatment
- Visits:
- 17 visits: 7 clinic visits, 3 overnight sleep-lab stays, 7 phone calls
- Compensation:
- Up to approximately $6,925 – $9,725 if you complete the study (amount depends on washout length). Travel, hotel, and meals reimbursed.
- You may qualify if:
- Adults 18–70 with narcolepsy type 2 · significant daytime sleepiness · BMI 18–40 · able to pause current sleep/wake medicines (paid washout)
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Narcolepsy Type 1 & 2 (HBS-301)
Efficacy and safety study of HBS-301 (a once-daily delayed-release form of pitolisant) in participants with narcolepsy, followed by an optional open-label extension.
- Duration:
- ~16 weeks including screening; optional 12-month open-label extension afterward
- Visits:
- At least 6 clinic visits including 2 overnight sleep-lab stays, plus telehealth visits
- Compensation:
- Approximately $1,834 if you complete the main study — including $700 for each of 2 overnight sleep-lab stays — plus additional payments in the optional extension. Travel reimbursed and arranged.
- You may qualify if:
- Adults 18+ with diagnosed narcolepsy (type 1 or 2) · significant daytime sleepiness · able to pause wake-promoting medicines · prior sleep study on file
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Idiopathic Hypersomnia (HBS-301)
Efficacy and safety study of HBS-301 (a once-daily delayed-release form of pitolisant) in participants with idiopathic hypersomnia (IH), followed by an optional open-label extension.
- Duration:
- ~16 weeks including screening; optional 12-month open-label extension afterward. No overnight sleep-lab stay required.
- Visits:
- At least 5 clinic visits plus telehealth visits; optional at-home EEG headband sub-study
- Compensation:
- Approximately $384 if you complete the main study, plus up to $900 more in an optional at-home EEG sub-study and additional payments in the optional extension. Travel reimbursed.
- You may qualify if:
- Adults 18+ with diagnosed idiopathic hypersomnia · significant daytime sleepiness · able to pause wake-promoting medicines · diagnostic sleep study on file
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Narcolepsy & Idiopathic Hypersomnia (ORX750-0201)
Study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational medicine ORX750 (cleminorexton) in adults with narcolepsy type 1 or 2 or idiopathic hypersomnia.
- Duration:
- Up to 12 weeks including screening (4-week treatment period)
- Visits:
- 2 overnight inpatient stays, up to 4 clinic visits, and 2 phone calls
- Compensation:
- Approximately $1,290 if you complete the study ($90 per visit; $250 per overnight stay). Travel, hotel, and meals arranged and prepaid separately — you don't pay out of pocket.
- You may qualify if:
- Adults 18–65 with narcolepsy type 1 or 2 or idiopathic hypersomnia · significant daytime sleepiness · willing to pause current sleep/wake medicines during the study
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Narcolepsy Type 1 & Type 2 (ORX750-004)
Also known as the SAPPHIRE study. Evaluating cleminorexton (ORX750), an investigational orexin-targeted medicine, compared with placebo in adults with narcolepsy. Type 1 and type 2 are enrolled as separate groups, each studied on its own.
- Duration:
- 12 weeks of daily study medicine, plus a screening period beforehand
- Visits:
- 3 overnight sleep-lab stays with next-day wakefulness testing (baseline, Week 4, and Week 12), plus clinic visits in between
- Compensation:
- Study-related care is provided at no cost. Travel, hotel, and meals are arranged and prepaid for you — or reimbursed up to $300 per visit if you prefer to make your own arrangements. Payment for your time is confirmed with you at your screening visit.
- You may qualify if:
- Adults 18–70 with a diagnosis of narcolepsy type 1 or narcolepsy type 2
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Obstructive Sleep Apnea — Sensor Study
A single-night study capturing airway sounds with a small wearable acoustic sensor strip (SOMNAR) worn on the face while you undergo your already-scheduled overnight sleep study (PSG).
- Duration:
- One night — during your already-scheduled sleep study
- Visits:
- 1 visit (your existing sleep-study appointment); no extra visits
- Compensation:
- $25 for participating
- You may qualify if:
- Adults already scheduled for an in-lab overnight sleep study · able to consent for yourself · willing to wear a small adhesive sensor strip during the night
This is a research study. Participation is voluntary and you may withdraw at any time. Study-related care is provided at no cost.
Prefer email? Write to research@dreamsleepmedicine.com.
Your Journey, Step by Step
No surprises. Here's exactly what happens after you reach out.
Email Us
Tell us your diagnosis and a bit about your symptoms so we know which studies to look at.
Pre-Screening Call
Our research coordinator calls to talk through your history and answer questions.
Free Screening Visit
We confirm eligibility with testing, at no cost — and you decide if it feels right.
Enroll & Begin
Start the study with your sleep physician following you the whole way.
Taking part is always your choice, and you can stop at any point. Before anything begins we sit down and walk you through the whole study, so you can decide with the full picture.
Past Research
Completed trials and studies that have contributed to advancing sleep medicine.
Eight Sleep Pod: Validation Against PSG
A validation study evaluating the Eight Sleep Pod for identification of respiratory events against gold-standard in-lab polysomnography. Enrollment is now closed.
Inspire® Therapy Pilots
We have been selected as a pilot site for multiple Inspire Medical Systems innovations, helping to validate new stimulation algorithms and sensing technologies before national rollout.
- • Adherence & Efficacy Pilots
- • Early-Stage Validation
Nyxoah Genio® USA Launch
Dream Sleep Medicine was one of the first sites in the USA to publish post-FDA approval data on the Genio® bilateral stimulation system.
Research Infrastructure
Ashley York, CRC
Ashley coordinates day-to-day trial operations at DSM Research — participant screening and scheduling, visit conduct, source documentation, and sponsor and monitor communication.
Our research operations follow ICH/GCP guidelines, with protocol execution and data integrity overseen directly by the Principal Investigator.
We are actively seeking industry partnerships for:
- Device Validation & CPAP Interface Research
- Phase 3 Drug Trials (Narcolepsy, Insomnia, OSA, Obesity)
Contact our Clinical Research Director to discuss site selection.
research@dreamsleepmedicine.com